Meletios Therapeutics
Company Details
Status: Private
Employees: 1-10
Location:
Paris, France
Type:
sample
Technology:
sample
sample
sample
About: Meletios Therapeutics’ aim is to fulfill the urgent and large unmet medical need for broad spectrum treatments against current and emerging viral infections.
This French biotech company was created in April 2020 by a team of high level scientists and experienced biotech managers.
One of our first drug candidate has confirmed its broad-spectrum potential in in vitro and in vivo models on the coronavirus family and influenza H1N1, demonstrating a dual antiviral and anti-inflammatory activity. This molecule will now be developed and tested in order to meet regulatory requirements and enter clinical phase II.
Several drug candidates from Meletios portfolio are currently being tested both in vitro and in vivo and will expand our range of antiviral molecules on different RNA viruses.
Meletios Therapeutics’ goal is to become a global leader in the fight against emerging viral infections by developing innovative broad-spectrum therapeutic solutions.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Meletios Therapeutics | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.